Literature DB >> 8348563

In vitro expansion and analysis of T lymphocyte microcultures obtained from the vaccination sites of cancer patients undergoing active specific immunization with autologous Newcastle-disease-virus-modified tumour cells.

M Stoeck1, C Marland-Noske, M Manasterski, R Zawatzky, S Horn, V Möbus, P Schlag, V Schirrmacher.   

Abstract

In order to understand further the effects of Newcastle-disease-virus(NDV)-modified tumour vaccines we investigated the feasibility of isolating lymphocytes from the site of injection of patients undergoing postoperative active specific immunization (ASI) with autologous NDV-modified tumour cells. Delayed-type-hypersensitivity(DTH)-like reactions from five cancer patients were surgically removed, minced and the tissue particles were digested with collagenase and DNase. Lymphoid cells recovered were expanded in a highly efficient limiting-dilution analysis system optimized for T cell growth [Moretta et al. (1983) J Exp Med 157: 743] and lymphocyte microcultures (clonal probability > 0.8) could be grown for up to 1 year. Analysis of the microcultures for phenotype and function showed that the majority were positive for CD4 (92%) and TCR alpha beta (96%). Concanavalin-A-induced production of interleukin-2 (IL-2), IL-6, interferon gamma and tumour necrosis factor alpha was detected in more than 70% of the microcultures. Lectin-dependent cytotoxicity was only very rarely observed. The general characteristics of the microcultures obtained support the notion of a DTH-like reaction taking place at the site of tumour cell challenge. The possibility of in vitro expansion and cultivation of T lymphocytes from ASI vaccination sites should help to elucidate further the role of these cells in active specific immunization against autologous tumour cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8348563     DOI: 10.1007/bf01518517

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  17 in total

Review 1.  Interferon-gamma: a review.

Authors:  J N Ijzermans; R L Marquet
Journal:  Immunobiology       Date:  1989-10       Impact factor: 3.144

Review 2.  Biological response modifiers: the new immunotherapy.

Authors:  K A Foon
Journal:  Cancer Res       Date:  1989-04-01       Impact factor: 12.701

3.  Separation, phenotyping and limiting dilution analysis of T-lymphocytes infiltrating human solid tumors.

Authors:  T L Whiteside; S Miescher; J Hurlimann; L Moretta; V von Fliedner
Journal:  Int J Cancer       Date:  1986-06-15       Impact factor: 7.396

4.  Non-specific propagation of human antigen-dependent T lymphocyte clones.

Authors:  B Fleischer
Journal:  J Immunol Methods       Date:  1988-05-09       Impact factor: 2.303

5.  Direct demonstration of the clonogenic potential of every human peripheral blood T cell. Clonal analysis of HLA-DR expression and cytolytic activity.

Authors:  A Moretta; G Pantaleo; L Moretta; J C Cerottini; M C Mingari
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

6.  Postoperative active specific immunization in colorectal cancer patients with virus-modified autologous tumor-cell vaccine. First clinical results with tumor-cell vaccines modified with live but avirulent Newcastle disease virus.

Authors:  W Bohle; P Schlag; W Liebrich; P Hohenberger; M Manasterski; P Möller; V Schirrmacher
Journal:  Cancer       Date:  1990-10-01       Impact factor: 6.860

7.  Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes.

Authors:  S A Rosenberg; S L Schwarz; P J Spiess
Journal:  J Natl Cancer Inst       Date:  1988-11-02       Impact factor: 13.506

8.  Postoperative active-specific immunotherapy of lymph node micrometastasis in a guinea pig tumor model.

Authors:  H Bier; G Armonat; J Bier; V Schirrmacher; U Ganzer
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  1989       Impact factor: 1.538

9.  Cellular and vascular manifestations of cell-mediated immunity.

Authors:  H F Dvorak; S J Galli; A M Dvorak
Journal:  Hum Pathol       Date:  1986-02       Impact factor: 3.466

10.  Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects.

Authors:  R Heicappell; V Schirrmacher; P von Hoegen; T Ahlert; B Appelhans
Journal:  Int J Cancer       Date:  1986-04-15       Impact factor: 7.396

View more
  3 in total

1.  Overexpression of p53 delivered using recombinant NDV induces apoptosis in glioma cells by regulating the apoptotic signaling pathway.

Authors:  Xiaoyong Fan; Hongzhen Lu; Youqiang Cui; Xianzeng Hou; Chuanjiang Huang; Guangcun Liu
Journal:  Exp Ther Med       Date:  2018-03-08       Impact factor: 2.447

2.  A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.

Authors:  F M Batliwalla; B A Bateman; D Serrano; D Murray; S Macphail; V C Maino; J C Ansel; P K Gregersen; C A Armstrong
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

3.  Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial.

Authors:  P Schlag; M Manasterski; T Gerneth; P Hohenberger; M Dueck; C Herfarth; W Liebrich; V Schirrmacher
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.